{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:58:09Z","timestamp":1792681089551,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.breast.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T17:30:29Z","timestamp":1689269429000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)"],"prefix":"10.1016","volume":"71","author":[{"given":"Hiroko","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6943","authenticated-orcid":false,"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2023.07.003_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib2","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.07.003_bib4","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib5","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2023.07.003_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41523-021-00289-7","article-title":"Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups","volume":"7","author":"Johnston","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2023.07.003_bib8","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"Monarch 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib9","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib10","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-related quality of life in MONARCH 3: abemaciclib plus an Aromatase inhibitor as initial therapy in HR+, HER2- advanced breast cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib11","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)\/HER2(-) breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2023.07.003_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/annonc\/mdu106","article-title":"The efficacy and safety of probiotics in people with cancer: a systematic review","volume":"25","author":"Redman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1748-717X-5-31","article-title":"Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients","volume":"5","author":"Chitapanarux","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib15","first-page":"105","article-title":"Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome","volume":"23","author":"Rahman","year":"2014","journal-title":"Mymensingh Med J"},{"key":"10.1016\/j.breast.2023.07.003_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2023.07.003_bib17","doi-asserted-by":"crossref","first-page":"x28","DOI":"10.1093\/annonc\/mdx654.004","article-title":"96O - MONARCH 2: abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy","volume":"28","author":"Toi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12282-021-01295-0","article-title":"Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"29","author":"Takahashi","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2023.07.003_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2023.07.003_bib20","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0959-8049(97)00395-X","article-title":"A cross-validation of the European Organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer","volume":"34","author":"Kobayashi","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2023.07.003_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib22","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib23","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/cas.14877","article-title":"Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials","volume":"112","author":"Toi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.breast.2023.07.003_bib25","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and degree of CDK drug interactions predicts clinical performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.breast.2023.07.003_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/toxsci\/kfaa092","article-title":"Phenotypic Characterization of targeted Knockdown of cyclin-dependent kinases in the intestinal epithelial cells","volume":"177","author":"Lu","year":"2020","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.breast.2023.07.003_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary Pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.breast.2023.07.003_bib28","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1046\/j.1440-1746.2003.03136.x","article-title":"Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer","volume":"18","author":"Gibson","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.breast.2023.07.003_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrgastro.2014.46","article-title":"Radiation enteropathy--pathogenesis, treatment and prevention","volume":"11","author":"Hauer-Jensen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.breast.2023.07.003_bib30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.47.5.632","article-title":"Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans","volume":"47","author":"Keefe","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.breast.2023.07.003_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2023.41.16_suppl.501","article-title":"Efficacy and safety results by age in monarchE: adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)","volume":"41","author":"Hamilton","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.003_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cas.15600","article-title":"Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: overall survival from MONARCH 2","volume":"114","author":"Toi","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.breast.2023.07.003_bib33","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2023.07.003_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/EDBK_238919","article-title":"The future of wearable technologies and remote monitoring in health care","volume":"39","author":"Liao","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2023.07.003_bib35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/CMAR.S348591","article-title":"Safety in Japanese advanced breast cancer patients who received abemaciclib in MONARCH 2 and MONARCH 3: Assessment of treatment-emergent neutropenia, diarrhea, and increased alanine aminotransferase and aspartate aminotransferase levels","volume":"14","author":"Masuda","year":"2022","journal-title":"Cancer Manag Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:46:37Z","timestamp":1760777197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623005180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"alternative-id":["S0960977623005180"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.003","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}